Humira launched in Japan for treatment of RA

29 June 2008

The Japanese unit of US health care major Abbott Laboratories and local drugmaker Eisai say that Humira (adalimumab) subcutaneous injection 40mg syringe 0.8mL was launched for the treatment of rheumatoid arthritis on June 18. The compound received approval for manufacturing and distribution in Japan on April 16 and was listed in the National Health Insurance drug price list on June 13. After its launch, Abbott and Eisai will use a one-brand, one-channel and two-promotion scheme to ensure provision of information on proper use of the tumor necrosis factor-alpha blocker. Both firms will provide specialist medical representatives, and Abbott will cooperate with Eisai's hospital MRs. The two companies will conduct post-marketing surveillance in patients receiving Humira injection during a certain period of time after launching to promote its effective and safe use.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight